Zacks Research Upgrades Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) to Hold

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Royal Bank Of Canada upped their price objective on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research note on Tuesday, February 24th. Raymond James Financial reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. Wall Street Zen downgraded Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, UBS Group reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Trading Up 1.6%

Shares of LKFT stock opened at $28.27 on Monday. Lakefront Biotherapeutics American Depositary Shares has a twelve month low of $26.42 and a twelve month high of $37.78. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -20.05 and a beta of 0.26. The stock has a fifty day simple moving average of $28.27 and a two-hundred day simple moving average of $31.19.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The firm had revenue of $1.06 billion during the quarter. Research analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Western Standard LLC purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the fourth quarter worth about $1,046,000. UBS Group AG raised its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 128.4% in the fourth quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after purchasing an additional 196,445 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter worth about $612,000. Aquatic Capital Management LLC raised its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 63.6% in the third quarter. Aquatic Capital Management LLC now owns 17,516 shares of the biotechnology company’s stock worth $607,000 after purchasing an additional 6,807 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in Lakefront Biotherapeutics American Depositary Shares during the second quarter worth about $560,000. 32.46% of the stock is currently owned by hedge funds and other institutional investors.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.